Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07365592

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

Location status: Recruiting

Location contact

Xinyi Zhou, MD

CONTACT

[email protected]

+86 18768115468

About this study

Most colorectal cancer (CRC) cases are classified as proficient mismatch repair (pMMR) CRC. This subtype is insensitive to single-agent immunotherapy, with chemotherapy remaining the primary pharmacotherapeutic intervention. Approximately 30% of colon cancer patients develop recurrence and metastasis following initial radical resection combined with 6 months of adjuvant chemotherapy.

Neoadjuvant chemotherapy (NACT) for tumor downstaging and survival improvement represents a standard approach for locally advanced tumors. However, its application is limited to select rectal cancer populations, and its role in colon cancer remains controversial-primarily due to inadequate tumor regression observed with current regimens. Given that deep tumor regression correlates with improved survival, there is a critical need to enhance NACT efficacy.

Neo-CD adopts a combined phase Ib/II study design. Phase Ib Component

  • Design: Single-center trial utilizing the traditional 3+3 dose-escalation principle.
  • Objectives:
  • Evaluate the safety of sitagliptin in combination with XELOX (oxaliplatin + capecitabine) and anti-PD-1 monoclonal antibody as neoadjuvant therapy for CRC.
  • Determine the recommended phase II dose (RP2D) of sitagliptin.
  • Explore the combination's potential for significant tumor regression and modulation of the tumor immune microenvironment.

Phase II Component

  • Design: Prospective, multicenter, randomized controlled superiority trial.
  • Objective: Compare the efficacy of neoadjuvant XELOX + sitagliptin + anti-PD-1 versus standard neoadjuvant XELOX in locally advanced CRC, with a focus on significant tumor regression (TRG 0/1 rate).

Study Procedures All participants will receive 2 cycles of the assigned neoadjuvant treatment, followed by radical surgery.

Primary Endpoints

  • Phase Ib: Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicity (DLT).
  • Phase II: Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically diagnosed colorectal adenocarcinoma
  • Age ≥18 years old and ≤75 years old
  • MRI/CT stage T3-4aNany and TanyN1-2, without distant metastasis
  • Life expectancy of 1 year The above
  • Informed consent, no contraindications to chemotherapy exist
  • pMMR diagnosed by IHC

Exclusion criteria

  • Refused to participate in this study
  • Multifocal colorectal cancer
  • Past history of malignant tumors, except for basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ
  • Unable to receive chemotherapy , such as but not limited to bone marrow suppression, etc
  • Major organ diseases (such as but not limited to COPD, coronary heart disease and renal insufficiency, etc.) acute attack and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.),
  • ASA score> 3
  • Mental disorder or illiteracy or language and communication barriers cannot understand the research plan
  • Colorectal tumor has obstruction or high risk of obstruction and or there is bleeding and/or perforation
  • Peripheral sensory nerve disorder, unable to receive oxaliplatin chemotherapy
  • Lateral pelvic lymph node metastasis (mainly supplied by internal iliac artery)
  • Pregnancy or breastfeeding
  • Unable to accept MRI examination
  • Consecutive use of glucocorticoids for more than 3 days within 1 month before signing the consent form
  • Diabetes or impaired glucose tolerance who may require drug intervention
  • Other scenarios deemed inappropriate by the investigators

Treatment and study plan

Oxaliplatin

Drug

Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.

Capecitabine

Drug

Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 2 cycles.

Anti-PD-1 monoclonal antibody

Drug

Anti-PD1 antibody 200mg/m2 in Day 1 after oxaliplatin Chemotherapy. Repeat every 3 weeks for 2 cycles.

Sitagliptin (DPP4 inhibitor)

Drug

Oral sitagliptin twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 2 cycles.

In the phase Ib study, sitagliptin set at three dose groups: 100 mg/day, 200 mg/day, and 400 mg/day, and the primary endpoint of Ib study is to determine the DLT and recommended phase II dose (RP2D).

The appropriate dose level of sitagliptin will be set based on the result of Ib study.

Primary outcomes

  1. Adverse events (AEs)

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study

  2. Dose limiting toxicities (DLTs)

    Time frame: The DLT observation period is from the day1 of the first cycle(C1D1) to the start of the day1 of the second cycle(C2D1) dosing, each cycle is 21 days.

    for Ib study

  3. Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1)

    Time frame: 1 day of postoperative pathological examination.

    for II study

Secondary outcomes

  1. Surgical Complication

    Time frame: within 30 days since operation

    for II study

  2. Proportion of patients achieving tumor regression grade 3 (TRG 3)

    Time frame: 1 day of postoperative pathological examination.

    for II study

  3. Adverse events (AEs)

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for II study

  4. Proportion of patients achieving tumor regression grade 0/1

    Time frame: 1 day of postoperative pathological examination.

    for Ib study

  5. Proportion of patients achieving pathological Complete Response

    Time frame: 1 day of postoperative pathological examination.

    for Ib study

  6. Proportion of patients achieving Major Pathologic Response

    Time frame: 1 day of postoperative pathological examination.

    for Ib study

  7. Area Under the Curve

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study；quantitative measure of the total exposure of the body to a drug over a specific time period.

  8. Maximum Concentration

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study; highest plasma or blood concentration of a drug achieved in the body after its administration.

  9. Time to Maximum Concentration

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study; the length of time required for a drug to reach its maximum (peak) plasma or blood concentration in the systemic circulation after administration.

  10. Clearance

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study; the volume of plasma or blood completely cleared of a drug per unit time by the body's eliminating organs

  11. Half-Life

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study; the specific time required for the plasma or blood concentration of a drug in the systemic circulation to decrease by half from its peak level or steady-state level

Other outcomes

  1. DPP4 activity in peripheral blood and tumor tissues

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

    for Ib study;

  2. The changes in the immunoprofile of the tumor tissue sample among TRG0/1 and TRG2/3 patients

    Time frame: 3 months after surgery

    By using single-cell analysis, we comprehensively characterized the immune landscape in the tumor sample of CRC patients before and after neoadjuvant treatment.

  3. 2-year overall survival

    Time frame: 2-year after surgery

    for II study; The proportion of all study cases in which no death from any cause occurred within 2 years after surgery

  4. 2-year Disease-free survival

    Time frame: From date of first chemotherapy until the date of first documented recurrence of tumor or date of death from any cause，whichever came first，assessed up to 24 months.

    From date of first chemotherapy until the date of first documented recurrence of tumor or date of death from any cause，whichever came first，assessed up to 24 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Jun Li, MD

CONTACT

[email protected]

+86 13777878061

Xinyi Zhou, MD

CONTACT

[email protected]

+86 18768115468

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

A Phase Ib/II Study of Neoadjuvant Chemotherapy Combined With Anti-PD-1 Antibody and DPP4 Inhibitor Sitagliptin for Locally Advanced pMMR Colorectal Cancer

Acronym: Neo-CD

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 26, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.